Pain in Paget's disease

A retrospective study of treatment efficacy

Alessandro Zati, Biagio Carmine Colori, Silvia Bonfiglioli Stagni, Annarosa Mignani

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

The authors addressed the role and the management of pain in Paget's disease by a retrospective study. The objectives were: to assess the presence of pain in Paget's disease; to look for a relationship between pain and the levels of total alkaline phosphatase (total ALP); to verify if the most commonly used drugs in Paget's disease, calcitonin and bisphosphonates, were able to reduce the pain and the levels of total ALP. The study analyzed 107 Italian patients with Paget's disease who were hospitalized at the same Institute between 1970 and 2010; all patients affected by severe arthritis were excluded. From the analysis of the clinical records it emerged that as many as 85% of patients had pain and that total ALP was also increased in most of the patients with pain in comparison with patients without pain. The clinical and metabolic effects of different therapies were then assessed: many patients had not received any specific therapy (58%), others had been treated with calcitonin (25%) and others with bisphosphonates (17%). In fact, the patients treated with bisphosphonates had significantly lower levels both of pain and total ALP. The authors hypothesize that the pain in Paget's disease has a primary origin and is correlated to the degree of bone metabolic hyperactivity. Finally, treatment with bisphosphonates appeared to be the most appropriate treatment, having been able to control both the pain and the metabolic hyperactivity.

Original languageEnglish
Pages (from-to)127-132
Number of pages6
JournalNeuroendocrinology Letters
Volume32
Issue number2
Publication statusPublished - 2011

Fingerprint

Retrospective Studies
Pain
Diphosphonates
Alkaline Phosphatase
Calcitonin
Pain Management
Therapeutics
Arthritis
Bone and Bones
Pharmaceutical Preparations

Keywords

  • Bisphosphonates
  • Calcitonin
  • Paget's disease
  • Pain

ASJC Scopus subject areas

  • Endocrinology
  • Endocrine and Autonomic Systems
  • Endocrinology, Diabetes and Metabolism
  • Clinical Neurology
  • Psychiatry and Mental health
  • Neurology

Cite this

Pain in Paget's disease : A retrospective study of treatment efficacy. / Zati, Alessandro; Colori, Biagio Carmine; Bonfiglioli Stagni, Silvia; Mignani, Annarosa.

In: Neuroendocrinology Letters, Vol. 32, No. 2, 2011, p. 127-132.

Research output: Contribution to journalArticle

Zati, A, Colori, BC, Bonfiglioli Stagni, S & Mignani, A 2011, 'Pain in Paget's disease: A retrospective study of treatment efficacy', Neuroendocrinology Letters, vol. 32, no. 2, pp. 127-132.
Zati, Alessandro ; Colori, Biagio Carmine ; Bonfiglioli Stagni, Silvia ; Mignani, Annarosa. / Pain in Paget's disease : A retrospective study of treatment efficacy. In: Neuroendocrinology Letters. 2011 ; Vol. 32, No. 2. pp. 127-132.
@article{dd67d39f0fef4a5b84636b7c976d4c5f,
title = "Pain in Paget's disease: A retrospective study of treatment efficacy",
abstract = "The authors addressed the role and the management of pain in Paget's disease by a retrospective study. The objectives were: to assess the presence of pain in Paget's disease; to look for a relationship between pain and the levels of total alkaline phosphatase (total ALP); to verify if the most commonly used drugs in Paget's disease, calcitonin and bisphosphonates, were able to reduce the pain and the levels of total ALP. The study analyzed 107 Italian patients with Paget's disease who were hospitalized at the same Institute between 1970 and 2010; all patients affected by severe arthritis were excluded. From the analysis of the clinical records it emerged that as many as 85{\%} of patients had pain and that total ALP was also increased in most of the patients with pain in comparison with patients without pain. The clinical and metabolic effects of different therapies were then assessed: many patients had not received any specific therapy (58{\%}), others had been treated with calcitonin (25{\%}) and others with bisphosphonates (17{\%}). In fact, the patients treated with bisphosphonates had significantly lower levels both of pain and total ALP. The authors hypothesize that the pain in Paget's disease has a primary origin and is correlated to the degree of bone metabolic hyperactivity. Finally, treatment with bisphosphonates appeared to be the most appropriate treatment, having been able to control both the pain and the metabolic hyperactivity.",
keywords = "Bisphosphonates, Calcitonin, Paget's disease, Pain",
author = "Alessandro Zati and Colori, {Biagio Carmine} and {Bonfiglioli Stagni}, Silvia and Annarosa Mignani",
year = "2011",
language = "English",
volume = "32",
pages = "127--132",
journal = "Neuroendocrinology Letters",
issn = "0172-780X",
publisher = "Maghira and Maas Publications",
number = "2",

}

TY - JOUR

T1 - Pain in Paget's disease

T2 - A retrospective study of treatment efficacy

AU - Zati, Alessandro

AU - Colori, Biagio Carmine

AU - Bonfiglioli Stagni, Silvia

AU - Mignani, Annarosa

PY - 2011

Y1 - 2011

N2 - The authors addressed the role and the management of pain in Paget's disease by a retrospective study. The objectives were: to assess the presence of pain in Paget's disease; to look for a relationship between pain and the levels of total alkaline phosphatase (total ALP); to verify if the most commonly used drugs in Paget's disease, calcitonin and bisphosphonates, were able to reduce the pain and the levels of total ALP. The study analyzed 107 Italian patients with Paget's disease who were hospitalized at the same Institute between 1970 and 2010; all patients affected by severe arthritis were excluded. From the analysis of the clinical records it emerged that as many as 85% of patients had pain and that total ALP was also increased in most of the patients with pain in comparison with patients without pain. The clinical and metabolic effects of different therapies were then assessed: many patients had not received any specific therapy (58%), others had been treated with calcitonin (25%) and others with bisphosphonates (17%). In fact, the patients treated with bisphosphonates had significantly lower levels both of pain and total ALP. The authors hypothesize that the pain in Paget's disease has a primary origin and is correlated to the degree of bone metabolic hyperactivity. Finally, treatment with bisphosphonates appeared to be the most appropriate treatment, having been able to control both the pain and the metabolic hyperactivity.

AB - The authors addressed the role and the management of pain in Paget's disease by a retrospective study. The objectives were: to assess the presence of pain in Paget's disease; to look for a relationship between pain and the levels of total alkaline phosphatase (total ALP); to verify if the most commonly used drugs in Paget's disease, calcitonin and bisphosphonates, were able to reduce the pain and the levels of total ALP. The study analyzed 107 Italian patients with Paget's disease who were hospitalized at the same Institute between 1970 and 2010; all patients affected by severe arthritis were excluded. From the analysis of the clinical records it emerged that as many as 85% of patients had pain and that total ALP was also increased in most of the patients with pain in comparison with patients without pain. The clinical and metabolic effects of different therapies were then assessed: many patients had not received any specific therapy (58%), others had been treated with calcitonin (25%) and others with bisphosphonates (17%). In fact, the patients treated with bisphosphonates had significantly lower levels both of pain and total ALP. The authors hypothesize that the pain in Paget's disease has a primary origin and is correlated to the degree of bone metabolic hyperactivity. Finally, treatment with bisphosphonates appeared to be the most appropriate treatment, having been able to control both the pain and the metabolic hyperactivity.

KW - Bisphosphonates

KW - Calcitonin

KW - Paget's disease

KW - Pain

UR - http://www.scopus.com/inward/record.url?scp=80051651786&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80051651786&partnerID=8YFLogxK

M3 - Article

VL - 32

SP - 127

EP - 132

JO - Neuroendocrinology Letters

JF - Neuroendocrinology Letters

SN - 0172-780X

IS - 2

ER -